Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) posted its quarterly earnings data on Friday. The company reported $999.00 EPS for the quarter, Zacks reports.
Appili Therapeutics Stock Performance
Shares of OTCMKTS APLIF opened at $0.01 on Friday. Appili Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.03. The stock’s fifty day moving average is $0.01 and its 200 day moving average is $0.01. The stock has a market capitalization of $1.50 million, a P/E ratio of -0.38 and a beta of -0.06.
About Appili Therapeutics
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Recommended Stories
- Five stocks we like better than Appili Therapeutics
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
